Biospecimen Acquistion and Molecular Annotation

生物样本采集和分子注释

• 批准号: 8375996
• 负责人: Mark A. Watson
• 金额: $ 13.73万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8375996
• 关键词: Administrator; Admission activity; Age; Aliquot; Autopsy; Bioinformatics; Biological Assay; Biostatistics Core; Blood; Books; Brain; Characteristics; Citrates; Clinical; Clinical Protocols; Clinical Trials; Coagulation Process; Collection; Common Data Element; Computers; Consent; Consent Forms; Correlative Study; DNA; Data; Databases; Date of birth; Development; Disease; Dry Ice; Edetic Acid; Enrollment; Equipment and supply inventories; Event; Extramural Activities; Failure; First Name; Freezing; Funding; Future; Gender; Generations; Genetic Polymorphism; Genomics; Goals; Hand; Health Insurance Portability and Accountability Act; Hour; Individual; Informed Consent; Institution; Institutional Review Boards; Intervention; Intraventricular; Judgment; Label; Last Name; Lead; Libraries; Liquid substance; Location; Malignant Neoplasms; Medical center; Modeling; Molecular; Names; Nitrogen; Nucleic Acids; Participant; Patient Discharge; Patient Recruitments; Patients; Peer Review; Peripheral; Phase; Plasma; Probability; Procedures; Process; Proteomics; Protocols documentation; Publications; Publishing; Race; Reading; Recording of previous events; Registries; Research; Research Infrastructure; Research Personnel; Resources; Review Committee; Role; Sampling; Science; Serum; Shunt Device; Specimen; Specimen Handling; Spectrum Analysis; Stroke; Stroke prevention; Symptoms; System; Technology; Time; Tissue Banking; Tissue Banks; Tissues; Transfusion; Tube; Universities; Washington; Whole Blood; Writing; absorption; base; blood product; clinical Diagnosis; data management; demographics; design; follow-up; hospital laboratories; human disease; inclusion criteria; novel; patient population; peripheral blood; programs; quality assurance; vapor; web-accessible

Adavnces in genomic and proteomic technologies have made the availability of biospecimens and corresponding data critical to understanding the molecular basis of human diseases such as stroke. Accordingly, the goal of the Biospecimen Procurement Core is to collect, process, store, and distribute biospecimens from patients in the context of both this proposal's clinical trials and during the routine treatment of patients at this medicial center. The first aim of this core is to support the collection and processing of serum, plasma, CSF, and genomic DMA from patients (approximately 50 per year) enrolled in studies described in projects 1-3. Samples will be collected upon study entry and over multiple time points as permissable, to create a set of biospecimens that can be analyzed over time and correlated with clinical progression. When available and appropriate, the core will also provide support to collect tissue specimens from patients. The second aim of this core is to create a more expansive biospecimen resource consisting of single time-point serum, plasma, and genomic DMA from all stroke patients (-800 per year) seen at this institution. The third aim of this core is to create an inventory of available biospecimen resources and deidentified data that can be accessed by authorized intramural and extramural SPOTRIAS investigators, for the purposes of sharing this biospecimen resource to promote novel clinical correlative studies in stroke prevention and treatment. To accomplish these goals, this core will capitalize on the extensive infrastructure that has already been developed for biospecimen management at our institution. Patient recruitment and consenting will be coordinated with Patient Core B. Biospecimens and associated data management will be coordinated with Biostatistics Core D and de-identified using a well-established honest broker mechanism. Specimen processing, storage, and quality assurance will utilize standardized operating procedures that have been in place in our institutional tissue bank for the past seven years. Generation and bioinformatic management of genomic polymorphism (SNP) data (although not specifically proposed in any of the current projects) will also be supported by the institution's GeneChip facility. Finally, biospecimen data management and data publishing will take advantage of efforts at our institution to develop an enterpriseclass, web-accessible biospecimen database (caTISSUE Core).

基因组学和蛋白质组学技术的进步使得生物标本和相应数据的可用性对于理解人类疾病（如中风）的分子基础至关重要。 因此，生物样本采购核心的目标是在本提案的临床试验和本医疗中心患者的常规治疗期间收集、处理、储存和分发患者的生物样本。该核心的首要目标是支持从入组项目1-3所述研究的患者（每年约50例）中采集和处理血清、血浆、CSF和基因组DNA。将在研究入组时和允许的多个时间点采集样本，以创建一组可随时间推移进行分析并与临床相关的生物标本。 进展在可用和适当的情况下，核心还将为收集患者组织标本提供支持。该核心的第二个目的是创建更广泛的生物样本资源，其由来自该机构的所有中风患者（每年约800例）的单个时间点血清、血浆和基因组DNA组成。该核心的第三个目标是创建可用生物标本资源的清单， 授权的院内外SPOTRIAS研究人员可以访问的数据，目的是共享该生物标本资源，以促进卒中预防和治疗的新临床相关研究。为了实现这些目标，该核心将利用我们机构已经为生物标本管理开发的广泛基础设施。患者招募和 同意将与患者核心B协调。生物标本和相关数据管理将与生物统计核心D协调，并使用完善的诚实中介机制去识别。 标本处理、储存和质量保证将利用我们机构组织库在过去七年中实施的标准化操作程序。基因组多态性（SNP）数据的生成和生物信息学管理（尽管在当前的任何项目中都没有具体提出）也将得到该机构基因芯片设施的支持。最后，生物标本数据管理和数据发布将利用我们机构的努力来开发企业级， 可通过网络访问的生物样本数据库（caTISSUE Core）。